# A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

> **NCT07190248** · PHASE3 · RECRUITING · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 675 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Calderasib
- **BIOLOGICAL:** Pembrolizumab (+) Berahyaluronidase alfa
- **DRUG:** Pemetrexed
- **DRUG:** Cisplatin
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT07190248
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-08
- **Primary completion:** 2029-12-07
- **Final completion:** 2032-08-06
- **Target enrollment:** 675 (ESTIMATED)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07190248

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07190248, "A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT07190248. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*